Monitoring of adenovirus (ADV)‐specific T cells in a boy with ADV pneumonia and disseminated disease after lung transplantation

Human adenovirus (ADV) infections are the cause of severe morbidity and mortality in transplant recipients. Cidofovir (CDV) is the current standard antiviral treatment. We report the case of a 3‐year‐old boy after lung transplantation with severe ADV sepsis, who was monitored for ADV‐specific T cell...

Full description

Saved in:
Bibliographic Details
Published in:Transplant infectious disease 2016-10, Vol.18 (5), p.756-760
Main Authors: Schultze‐Florey, R.E., Tischer, S., Schwerk, N., Heim, A., Eiz‐Vesper, B., Maecker‐Kolhoff, B.
Format: Article
Language:English
Subjects:
Adenoviridae - isolation & purification
adenovirus
Adenovirus Infections, Human - diagnosis
Adenovirus Infections, Human - drug therapy
Adenovirus Infections, Human - virology
ADV
ADV‐specific T cells
Antiviral Agents - administration & dosage
Antiviral Agents - therapeutic use
Bronchoalveolar Lavage Fluid - virology
Child, Preschool
Cytosine - administration & dosage
Cytosine - analogs & derivatives
Cytosine - therapeutic use
Enzyme-Linked Immunospot Assay
Feasibility Studies
Flow Cytometry
Humans
Immunocompromised Host
Immunosuppression - adverse effects
lung transplantation
Lung Transplantation - adverse effects
Lymphocytes
Male
monitoring
Monitoring, Physiologic - methods
Organophosphonates - administration & dosage
Organophosphonates - therapeutic use
pediatric
Pneumonia, Viral - diagnosis
Pneumonia, Viral - drug therapy
Pneumonia, Viral - virology
Real-Time Polymerase Chain Reaction
T-Lymphocytes - immunology
T-Lymphocytes - virology
Transplants & implants
Viral Load
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Human adenovirus (ADV) infections are the cause of severe morbidity and mortality in transplant recipients. Cidofovir (CDV) is the current standard antiviral treatment. We report the case of a 3‐year‐old boy after lung transplantation with severe ADV sepsis, who was monitored for ADV‐specific T cells during his disease and recovery. A strong increase in ADV‐specific T cells was accompanied by resolution of ADV in blood and bronchoalveolar lavage fluid. Antiviral treatment with CDV was individually adapted according to anti‐ADV immune responses, which provides a new method for tailoring antiviral treatment in lung transplant recipients.
ISSN:1398-2273
1399-3062
DOI:10.1111/tid.12569